Status:
COMPLETED
Safety and Feasibility of Dasatinib and Quercetin in Adults at Risk for Alzheimer's Disease
Lead Sponsor:
Lewis Lipsitz
Conditions:
Aging
Eligibility:
All Genders
65+ years
Phase:
PHASE1
PHASE2
Brief Summary
The purpose of this pilot study is to demonstrate the safety and feasibility of administering intermittent doses of Dasatinib and Quercetin (D+Q) in older adults at risk of Alzheimer's disease (AD). T...
Detailed Description
The investigators will conduct a 12-week single arm, open label, pre-post pilot study in 12 adults aged 65 or older with slow gait speed (\<1.0 m/sec) and Mild Cognitive Impairment (MCI, defined as a ...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Men and women \>/= 65 years
- Ambulatory,
- Community dwelling,
- Slow gait speed (\<1 m/second),
- Mild Cognitive Impairment (Telephone MoCA score \<21, which is indicative of cognitive impairment)
- Exclusion Criteria, or as per clinical judgment:
- Telephone MoCA score \<10 points
- Unwilling to take study medications or follow study protocol
- Inability to independently perform Katz Activities of Daily Living (ADLs),
- Allergies to Dasatinib or Quercetin,
- Hospitalization within 6 months,
- Unstable coronary artery disease (myocardial infarction within 6 months or angina),
- Stroke or transient ischemic attack in the past 6 months,
- Chronic heart failure,
- Current or chronic history of liver disease,
- Neurodegenerative disease including Parkinson's disease,
- Anemia,
- Chronic renal disease,
- Drug or alcohol abuse in the last 5 years,
- QTc prolongation,
- Thrombocytopenia,
- Neutropenia,
- Prolonged prothrombin time or INR,
- Indications of current fluid retention,
- History or current diagnosis of pulmonary hypertension,
- Inability to insonate the middle cerebral artery through a temporal bone window on at least one side using transcranial Doppler ultrasound, or
- Chronic use of any of the following medications: anti-arrhythmic medications, antipsychotics, anxiolytics, anti-platelet or anti-coagulant medications other than aspirin, quinolone antibiotics, or drugs metabolized by the same liver enzymes as Quercetin or Dasatinib.
Exclusion
Key Trial Info
Start Date :
May 20 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 24 2024
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT05422885
Start Date
May 20 2022
End Date
January 24 2024
Last Update
March 17 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hebrew Senior Life
Boston, Massachusetts, United States, 02131